Time-to-event modelling of effect of codrituzumab on overall survival in patients with hepatocellular carcinoma.

The final model indicates that adequate drug exposure plus a favourable immune environment are associated with prolonged OS. This quantitative model should be further validated with emerging data so as to guide study design in future clinical trials.